Literature DB >> 26574670

Transmission of Soluble and Insoluble α-Synuclein to Mice.

Daryl Rhys Jones1, Marion Delenclos, AnnMarie T Baine, Michael DeTure, Melissa E Murray, Dennis W Dickson, Pamela J McLean.   

Abstract

The neurodegenerative synucleinopathies, which include Parkinson disease, multiple-system atrophy, and Lewy body disease, are characterized by the presence of abundant neuronal inclusions called Lewy bodies and Lewy neurites. These disorders remain incurable, and a greater understanding of the pathologic processes is needed for effective treatment strategies to be developed. Recent data suggest that pathogenic misfolding of the presynaptic protein, α-synuclein (α-syn), and subsequent aggregation and accumulation are fundamental to the disease process. It is hypothesized that the misfolded isoform is able to induce misfolding of normal endogenous α-syn, much like what occurs in the prion diseases. Recent work highlighting the seeding effect of pathogenic α-syn has largely focused on the detergent-insoluble species of the protein. In this study, we performed intracerebral inoculations of the sarkosyl-insoluble or sarkosyl-soluble fractions of human Lewy body disease brain homogenate and show that both fractions induce CNS pathology in mice at 4 months after injection. Disease-associated deposits accumulated both near and distal to the site of the injection, suggesting a cell-to-cell spread via recruitment of α-syn. These results provide further insight into the prion-like mechanisms of α-syn and suggest that disease-associated α-syn is not homogeneous within a single patient but might exist in both soluble and insoluble isoforms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26574670      PMCID: PMC4654695          DOI: 10.1097/NEN.0000000000000262

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  45 in total

Review 1.  Transmission of prions.

Authors:  C Weissmann; M Enari; P-C Klöhn; D Rossi; E Flechsig
Journal:  J Infect Dis       Date:  2002-12-01       Impact factor: 5.226

2.  The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy.

Authors:  P Brown; R G Rohwer; B C Dunstan; C MacAuley; D C Gajdusek; W N Drohan
Journal:  Transfusion       Date:  1998-09       Impact factor: 3.157

3.  Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay.

Authors:  Julie Ann Edgeworth; Michael Farmer; Anita Sicilia; Paul Tavares; Jonathan Beck; Tracy Campbell; Jessica Lowe; Simon Mead; Peter Rudge; John Collinge; Graham S Jackson
Journal:  Lancet       Date:  2011-02-05       Impact factor: 79.321

4.  Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1.

Authors:  Eun-Jung Lee; Moon-Sook Woo; Pyong-Gon Moon; Moon-Chang Baek; In-Young Choi; Won-Ki Kim; Eunsung Junn; Hee-Sun Kim
Journal:  J Immunol       Date:  2010-05-28       Impact factor: 5.422

Review 5.  Species-barrier phenomenon in prion transmissibility from a viewpoint of protein science.

Authors:  Ken'ichi Hagiwara; Hideyuki Hara; Kentaro Hanada
Journal:  J Biochem       Date:  2013-01-02       Impact factor: 3.387

6.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

Review 7.  Metal ions and infectious diseases. An overview from the clinic.

Authors:  Peggy L Carver
Journal:  Met Ions Life Sci       Date:  2013

8.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation.

Authors:  Jia-Yi Li; Elisabet Englund; Janice L Holton; Denis Soulet; Peter Hagell; Andrew J Lees; Tammaryn Lashley; Niall P Quinn; Stig Rehncrona; Anders Björklund; Håkan Widner; Tamas Revesz; Olle Lindvall; Patrik Brundin
Journal:  Nat Med       Date:  2008-04-06       Impact factor: 53.440

9.  Prion-like spreading of pathological α-synuclein in brain.

Authors:  Masami Masuda-Suzukake; Takashi Nonaka; Masato Hosokawa; Takayuki Oikawa; Tetsuaki Arai; Haruhiko Akiyama; David M A Mann; Masato Hasegawa
Journal:  Brain       Date:  2013-03-06       Impact factor: 13.501

10.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  10 in total

Review 1.  Neurodegenerative Disease Transmission and Transgenesis in Mice.

Authors:  Brittany N Dugger; Daniel P Perl; George A Carlson
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 2.  Calcium and Parkinson's disease.

Authors:  D James Surmeier; Paul T Schumacker; Jaime D Guzman; Ema Ilijic; Ben Yang; Enrico Zampese
Journal:  Biochem Biophys Res Commun       Date:  2016-08-30       Impact factor: 3.575

3.  Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Authors:  Joseph Jankovic; Ira Goodman; Beth Safirstein; Tonya K Marmon; Dale B Schenk; Martin Koller; Wagner Zago; Daniel K Ness; Sue G Griffith; Michael Grundman; Jay Soto; Susanne Ostrowitzki; Frank G Boess; Meret Martin-Facklam; Joseph F Quinn; Stuart H Isaacson; Omid Omidvar; Aaron Ellenbogen; Gene G Kinney
Journal:  JAMA Neurol       Date:  2018-10-01       Impact factor: 18.302

4.  Decreased AQP4 Expression Aggravates ɑ-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance.

Authors:  Huili Cui; Wenkang Wang; Xinhui Zheng; Danhao Xia; Han Liu; Chi Qin; Haiyan Tian; Junfang Teng
Journal:  J Mol Neurosci       Date:  2021-03-26       Impact factor: 3.444

Review 5.  Prion-like properties of the mutant huntingtin protein in living organisms: the evidence and the relevance.

Authors:  Melanie Alpaugh; Hélèna L Denis; Francesca Cicchetti
Journal:  Mol Psychiatry       Date:  2022-01       Impact factor: 15.992

6.  Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Authors:  Brian Spencer; Elvira Valera; Edward Rockenstein; Cassia Overk; Michael Mante; Anthony Adame; Wagner Zago; Peter Seubert; Robin Barbour; Dale Schenk; Dora Games; Robert A Rissman; Eliezer Masliah
Journal:  Acta Neuropathol Commun       Date:  2017-01-13       Impact factor: 7.801

7.  LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons.

Authors:  Anwesha Sanyal; Hailey S Novis; Emile Gasser; Steven Lin; Matthew J LaVoie
Journal:  Front Neurosci       Date:  2020-05-15       Impact factor: 4.677

8.  Autonomic ganglionic injection of α-synuclein fibrils as a model of pure autonomic failure α-synucleinopathy.

Authors:  Xue-Jing Wang; Ming-Ming Ma; Le-Bo Zhou; Xiao-Yi Jiang; Miao-Miao Hao; Robert K F Teng; Erxi Wu; Bei-Sha Tang; Jia-Yi Li; Jun-Fang Teng; Xue-Bing Ding
Journal:  Nat Commun       Date:  2020-02-18       Impact factor: 14.919

9.  Transmission of α-synucleinopathy from olfactory structures deep into the temporal lobe.

Authors:  Daniel M Mason; Negin Nouraei; Deepti B Pant; Kristin M Miner; Daniel F Hutchison; Kelvin C Luk; John F Stolz; Rehana K Leak
Journal:  Mol Neurodegener       Date:  2016-06-30       Impact factor: 14.195

10.  Alpha-synuclein overexpression in the olfactory bulb initiates prodromal symptoms and pathology of Parkinson's disease.

Authors:  Haichen Niu; Lingyu Shen; Tongzhou Li; Chao Ren; Sheng Ding; Lei Wang; Zhonghai Zhang; Xiaoyu Liu; Qiang Zhang; Deqin Geng; Xiujuan Wu; Haiying Li
Journal:  Transl Neurodegener       Date:  2018-09-28       Impact factor: 8.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.